CCM Biosciences breaks out of stealth with $25M; Two biotechs merge, to focus on Parkinson's
CCM Biosciences launched out of stealth Tuesday, touting ten drug programs and more than $25 million raised from Series A1 and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
